Glycosylation of autoantibodies: Insights into the mechanisms of immune thrombocytopenia

Summary

Immune thrombocytopenia (ITP) is a bleeding disorder caused by IgG autoantibodies (AAbs) directed against platelets (PLTs). IgG effector functions depend on their Fc-constant region which undergoes post-translational glycosylation. We investigated the role of Asn279-linked N-glycan of AAbs in vitro and in vivo. AAbs were purified from ITP patients (n=15) and N-glycans were enzymatically cleaved by endoglycosidase F. The effects of native AAbs and deglycosylated AAbs were compared in vitro on enhancement of phagocytosis of platelets by monocytes and complement fixation and activation applying flow cytometry, laser scanning microscopy, and a complement consumption assay. AAb-induced platelet phagocytosis was inhibited by N-glycan cleavage (median phagocytic activity: 8% vs 0.8%, p=0.004). Seven out of 15 native AAbs bound C1q and activated complement. N-glycan cleavage significantly reduced both effects. In vivo survival of human PLTs was assessed after co-transfusion with native or N-glycan cleaved AAbs in a NOD/SCID mouse model. Injection of AAbs resulted in rapid clearance of human platelets compared to control (platelet clearance after 5h (CL_5h) 75% vs 30%, p<0.001). AAbs that were able to activate complement induced more pronounced platelet clearance in the presence of complement compared to the clearance in the absence of complement (CL_5h 82% vs 62%, p=0.003). AAbs lost their ability to destroy platelets in vivo after deglycosylation (CL_5h 42%, p<0.001). N-glycosylation of human ITP AAbs appears to be required for platelet phagocytosis and complement activation, reducing platelet survival in vivo. Posttranslational modification of AAbs may constitute an important determinant for the clinical manifestation of ITP.

Keywords

Thrombocytopenia - autoantibody - ITP - animal model - complement

• References

• 1 Rodeghiero F, Stasi R, Gernsheimer T. et al. Standardisation of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-93.
• 2 Provan D, Stasi R, Newland AC. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-186.
• 3 Cines DB, Bussel JB, Liebman HA. et al. The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113: 6511-6521.
• 4 McMillan R. The role of antiplatelet autoantibody assays in the diagnosis of immune thrombocytopenic purpura. Curr Hematol Rep 2005; 4: 160-165.
• 5 McMillan R, Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol 2005; 81: 94-99.
• 6 Nugent D, McMillan R, Nichol JL. et al. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009; 146: 585-596.
• 7 Olsson B, Andersson PO, Jernas M. et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9: 1123-1124.
• 8 Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol 2009; 46: S2-14.
• 9 Cines DB, Liebman HA. The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation. Hematol Oncol Clin North Am 2009; 23: 1155-1161.
• 10 Kiefel V, Santoso S, Mueller-Eckhardt C. Serological, biochemical, and molecular aspects of platelet autoantigens. Semin Hematol 1992; 29: 26-33.
• 11 Tomer A, Koziol J, McMillan R. Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated autoantibodies against platelet-specific receptors. J Thromb Haemost 2005; 3: 74-78.
• 12 McMillan R, Longmire RL, Tavassoli M, Armstrong S, Yelenosky R. In vitro platelet phagocytosis by splenic leukocytes in idiopathic thrombocytopenic purpura. N Engl J Med 1974; 290: 249-251.
• 13 Tsubakio T, Tani P, Curd JG, McMillan R. Complement activation in vitro by antiplatelet antibodies in chronic immune thrombocytopenic purpura. Br J Haematol 1986; 63: 293-300.
• 14 McKenzie SE, Taylor SM, Malladi P. et al. The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol 1999; 162: 4311-4318.
• 15 Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19: 275-290.
• 16 Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann NY Acad Sci 2012; 1253: 170-180.
• 17 Anthony RM, Nimmerjahn F. The role of differential IgG glycosylation in the interaction of antibodies with FcgammaRs in vivo. Curr Opin Organ Transplant 2011; 16: 7-14.
• 18 Collin M, Shannon O, Bjorck L. IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions. Proc Natl Acad Sci USA 2008; 105: 4265-4270.
• 19 Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34-47.
• 20 Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev 2010; 236: 265-275.
• 21 Ravetch JV, Luster AD, Weinshank R. et al. Structural heterogeneity and functional domains of murine immunoglobulin G Fc receptors. Science 1986; 234: 718-725.
• 22 Liang SX, Pinkevych M, Khachigian LM. et al. Drug-induced thrombocytopenia: development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG. Blood 2010; 116: 1958-1960.
• 23 Bakchoul T, Zollner H, Amiral J. et al. Anti-protamine-heparin antibodies: incidence, clinical relevance and pathogenesis. Blood 2013; 121: 2821-2827.
• 24 Bougie DW, Nayak D, Boylan B. et al. Drug-dependent clearance of human platelets in the NOD/scid mouse by antibodies from patients with drug-induced immune thrombocytopenia. Blood 2010; 116: 3033-3038.
• 25 Najaoui A, Bakchoul T, Stoy J. et al. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol 2012; 88: 167-174.
• 26 Kiefel V, Santoso S, Weisheit M. et al. Monoclonal antibody--specific immobilisation of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987; 70: 1722-1726.
• 27 Kiefel V. The MAIPA assay and its applications in immunohaematology. Transfus Med 1992; 2: 181-188.
• 28 Bakchoul T, Boylan B, Sachs UJ. et al. Blockade of maternal anti-HPA-1a-mediated platelet clearance by an HPA-1a epitope-specific F(ab') in an in vivo mouse model of alloimmune thrombocytopenia. Transfusion 2009; 49: 265-270.
• 29 Bakchoul T, Kubiak S, Krautwurst A. et al. Low-avidity anti-HPA-1a alloanti-bodies are capable of antigen-positive platelet destruction in the NOD/SCID mouse model of alloimmune thrombocytopenia. Transfusion 2011; 51: 2455-2461.
• 30 Shultz LD, Schweitzer PA, Christianson SW. et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995; 154: 180-191.
• 31 White KD, Cummings RD, Waxman FJ. Ig N-glycan orientation can influence interactions with the complement system. J Immunol 1997; 158: 426-435.
• 32 Peerschke EI, Andemariam B, Yin W. et al. Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol 2010; 148: 638-645.
• 33 Banda NK, Wood AK, Takahashi K. et al. Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. Arthritis Rheum 2008; 58: 3081-3089.
• 34 Chapin J, Weksler B, Magro C. et al. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012; 157: 772-774.
• 35 Shapira I, Andrade D, Allen SL. et al. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 2012; 64: 2719-2723.